Golbourn B, Ho B, Bondoc A et al “A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup ATRTs.” Neuro Oncol. (2024)

Ho, B., Arnoldo, A., Zhong, Y. et al. “Rapid, economical diagnostic classification of ATRT molecular subgroup using NanoString nCounter platform”. Neurooncol Adv. (2023)

Khan, S., Solano-Paez, P., Suwal, T et al. Clinical phenotypes and prognostic features of ETMRs (Embryonal Tumor with Multi-layered Rosettes) a new CNS tumor entity: A Rare Brain Tumor Registry study. The Lancet Child & Adolescent Health.(2021)

Liu, A.P.Y., Li, B.K., Pfaff, E. et al. Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathol (2021).

Chung P, et al. Modeling germline mutations in pineoblastoma uncovers lysosome disruption- based therapy. Nat Commun. 2020 Apr 14;11(1):1825.

Reddy A,et al. Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group Trial ACNS0333. J Clin Oncol. 2020 Apr 10;38(11):1175-1185.

Hoffman LM, Richardson EA, et al. Advancing biology based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro Oncol. 2020 Jul 7;22(7):944-954.

Ho B, Johann PD, Grabovska Y, et al. Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus. Neuro Oncol. 2020;22(5):613-624. doi:10.1093/neuonc/noz235

Li, B.K., Vasiljevic, A., Dufour, C. et al. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathol 139, 223–241 (2020). https://doi.org/10.1007/s00401-019-02111-y

Sin-Chan P, Mumal I, Suwal T, et al. A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell. 2019;36(1):51-67.e7. doi:10.1016/j.ccell.2019.06.002

Lambo S, Gröbner SN et al. The molecular landscape of ETMR at diagnosis and relapse. Nature. 2019 Dec;576(7786):274-280.

Torchia J, Golbourn B, Feng S, et al. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell. 2016;30(6):891-908. doi:10.1016/j.ccell.2016.11.003

Torchia J, Picard D, Lafay-Cousin L, et al. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol. 2015;16(5):569-582. doi:10.1016/S1470-2045(15)70114-2

Spence T, Sin-Chan P, Picard D, et al. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014;128(2):291-303. doi:10.1007/s00401-014-1291-1

Kleinman CL, Gerges N, Papillon-Cavanagh S, et al. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet. 2014;46(1):39-44. doi:10.1038/ng.2849

Spence T, Perotti C, Sin-Chan P, et al. A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes. Neuro Oncol. 2014;16(1):62-71. doi:10.1093/neuonc/not162

Sin-Chan P, Huang A. DNMTs as potential therapeutic targets in high-risk pediatric embryonal brain tumors. Expert Opin Ther Targets. 2014;18(10):1103-1107. doi:10.1517/14728222.2014.938052

Fried I, Huang A, Bartels U, et al. Chronic residual lesions in metastatic medulloblastoma patients. J Pediatr Hematol Oncol. 2014;36(1):71-75. doi:10.1097/MPH.0b013e3182843b40

Picard D, Miller S, Hawkins CE, et al. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol. 2012;13(8):838-848. doi:10.1016/S1470-2045(12)70257-7

Zhou L, Picard D, Ra YS, et al. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma. Cancer Res. 2010;70(20):8199-8210. doi:10.1158/0008-5472.CAN-09-4562

Li M, Lee KF, Lu Y, et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009;16(6):533-546. doi:10.1016/j.ccr.2009.10.025